Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial (ALEC)
Primary Purpose
Preterm Birth, Obstetric Labor, Premature, Obstetric Labor Complications
Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Azithromycin 1 gram IV
Cefazolin and indomethacin
Sponsored by
About this trial
This is an interventional treatment trial for Preterm Birth focused on measuring cerclage, preterm birth, premature cervical dilation, antibiotics
Eligibility Criteria
Inclusion Criteria:
- Pregnant women with singleton pregnancies
- ≥18 years old
- Estimated gestational age less than 24 weeks
- Meet criteria for an exam indicated cerclage
- Patients must also be able to provide consent, demonstrate an understanding of the purpose of the study, and agree to the study protocol.
Exclusion Criteria:
- Human immunodeficiency virus (HIV) positive status
- Known prolonged QT syndrome
- Major fetal congenital anomalies
- Temperature of 100.4 F or higher
- Prior cerclage during the current pregnancy
- Contraindication to indomethacin
- Allergy to both penicillin and clindamycin
- Received indomethacin or any antibiotics within 7 days before their presentation
Sites / Locations
- Northwestern UniversityRecruiting
- Rutgers Robert Wood JohnsonRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Experimental
Arm Label
Cefazolin and Indomethacin
Azithromycin + control
Arm Description
Control arm- perioperative cefazolin and indomethacin
perioperative azithromycin, cefazolin and indomethacin
Outcomes
Primary Outcome Measures
Gestational Latency Achieved Between Cerclage Placement and Time of Delivery
Mean gestational latency achieved Between Cerclage Placement and Time of Delivery
Secondary Outcome Measures
Preterm birth <37 weeks, <34 weeks, <32 weeks, <28 weeks, <24 weeks
Preterm delivery stratified by gestational age at delivery in weeks
Mean gestational age at delivery
Measured in weeks
chorioamnionitis
Histologic or clinical diagnosis
birth weight
measured in grams
Admission to neonatal intensive care unit
If admitted, measured in days
Neonatal Morbidity and Mortality
including apgars, Respiratory Distress Syndrome, Bronchopulmonary dysplasia, Retinopathy of prematurity, Intraventricular hemorrhage (IVH) (grade 3 or 4), patent ductus arteriosus, and neonatal death
Cervicovaginal cytokine analysis
Measurement of proinflammatory cytokines in pg/ml (IL-1B, IL-2, IL-4, IL-6, IL-8, IL-8, IL-10, G-CSF, GM-CSF, MCP-1, TNF-a, IFN-g, CCL5, VEGF, ICAM-1) from cervicovaginal fluid at the time of cerclage placement and at follow up 1-4 weeks after placement
Full Information
NCT ID
NCT05132829
First Posted
October 25, 2021
Last Updated
June 23, 2023
Sponsor
Thomas Jefferson University
1. Study Identification
Unique Protocol Identification Number
NCT05132829
Brief Title
Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial
Acronym
ALEC
Official Title
Azithromycin to Improve Latency in Exam Indicated Cerclage: a Randomized Control Trial
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 20, 2021 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
June 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Thomas Jefferson University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Azithromycin is an antibiotic that is effective against bacteria that been associated with preterm birth (PTB). The purpose of this study is to evaluate if the addition of azithromycin prior to exam indicated cerclage prolongs gestation. A cerclage is a suture placed in the cervix to prolong gestation.
Detailed Description
Preterm birth (PTB) continues to be a leading cause of neonatal morbidity and mortality. The rate of spontaneous PTB (delivery before 37 weeks gestation) is one in ten pregnancies and a history of prior preterm birth remains a risk factor for recurrence. The pathophysiology of cervical insufficiency leading to PTB remains poorly understood.
While interventions for PTB prevention are limited, the American College of Obstetrics and Gynecology (ACOG) supports the use of cervical cerclage. A physical exam indicated cerclage may be placed in the setting of painless cervical dilation in the second trimester. The cerclage is believed to provide mechanical support to a weakened cervix and promote the cervical mucosal plug as a barrier to ascending infection.
While many aspects of cerclage use have been extensively studied, the use of antibiotics prior to placement remains under evaluated. While antibiotic use is recommended during cesarean section, preterm premature rupture of membranes (PPROM), and obstetric anal sphincter injuries (OASIS), ACOG currently does not recommend perioperative antibiotics or prophylactic tocolytics at the time of cerclage placement citing insufficient evidence.
Miller et al. performed a randomized controlled trial (RCT) showing an increased incidence of pregnancy prolongation by at least 28 days among women who received indomethacin and perioperative antibiotics in the setting of an exam indicated cerclage compared to those who received no perioperative medications (92.3% vs 62.5%, p=0.01). Participants in the experimental arm received cefazolin or clindamycin if they had a penicillin allergy. Cefazolin is a first generation cephalosporin that has activity against gram positive cocci and gram negative rods and is commonly used for surgical prophylaxis. Clindamycin is a protein synthesis inhibitor and covers gram positive organisms and anaerobic bacteria, making it an appropriate alternative in cases of penicillin allergy. The use of cefazolin specifically with indomethacin has been studied retrospectively and showed a significant improvement in gestational latency (adjusted relative risk [aRR] 1.21, 95% CI 1.05-1.40) and birth weight (+489.8 grams, 95% CI 64.6-915.0).
The use of prolonged azithromycin with cerclage has been studied in a prospective, non- randomized fashion. In this study, patients were given 500mg azithromycin for 3 days and this was repeated every 10 days until 34 weeks. Patients who received this regimen and a cerclage had lower PTB (65.7% vs 5.7%, p<0.001) and reduced immediate fetal mortality (37.1% vs 0%, p<0.001).
The aim of our study is to determine if the addition of azithromycin prior to exam indicated cerclage prolongs gestation. Azithromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome and inhibits transpeptidation. It is effective against a wide variety of bacteria, specifically mycoplasma which has been associated with preterm birth. Azithromycin is currently used in obstetrics for patients undergoing nonelective cesarean delivery and as part of latency antibiotics in the setting of PPROM.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Preterm Birth, Obstetric Labor, Premature, Obstetric Labor Complications, Pregnancy Complications, Physiological Effects of Drugs, Uterine Cervical Incompetence, Anti-Bacterial Agents, Azithromycin, Cefazolin
Keywords
cerclage, preterm birth, premature cervical dilation, antibiotics
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Cefazolin and Indomethacin
Arm Type
Other
Arm Description
Control arm- perioperative cefazolin and indomethacin
Arm Title
Azithromycin + control
Arm Type
Experimental
Arm Description
perioperative azithromycin, cefazolin and indomethacin
Intervention Type
Drug
Intervention Name(s)
Azithromycin 1 gram IV
Intervention Description
Perioperative addition of azithromycin at the time of physical exam indicated cerclage placement.
Intervention Type
Drug
Intervention Name(s)
Cefazolin and indomethacin
Intervention Description
Perioperative standard of care with cefazolin and indomethacin
Primary Outcome Measure Information:
Title
Gestational Latency Achieved Between Cerclage Placement and Time of Delivery
Description
Mean gestational latency achieved Between Cerclage Placement and Time of Delivery
Time Frame
24 weeks following cerclage placement
Secondary Outcome Measure Information:
Title
Preterm birth <37 weeks, <34 weeks, <32 weeks, <28 weeks, <24 weeks
Description
Preterm delivery stratified by gestational age at delivery in weeks
Time Frame
at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Title
Mean gestational age at delivery
Description
Measured in weeks
Time Frame
at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Title
chorioamnionitis
Description
Histologic or clinical diagnosis
Time Frame
at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Title
birth weight
Description
measured in grams
Time Frame
at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Title
Admission to neonatal intensive care unit
Description
If admitted, measured in days
Time Frame
at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Title
Neonatal Morbidity and Mortality
Description
including apgars, Respiratory Distress Syndrome, Bronchopulmonary dysplasia, Retinopathy of prematurity, Intraventricular hemorrhage (IVH) (grade 3 or 4), patent ductus arteriosus, and neonatal death
Time Frame
within 28 days of delivery
Title
Cervicovaginal cytokine analysis
Description
Measurement of proinflammatory cytokines in pg/ml (IL-1B, IL-2, IL-4, IL-6, IL-8, IL-8, IL-10, G-CSF, GM-CSF, MCP-1, TNF-a, IFN-g, CCL5, VEGF, ICAM-1) from cervicovaginal fluid at the time of cerclage placement and at follow up 1-4 weeks after placement
Time Frame
Cerclage placement and 1-4 weeks after
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Pregnant women with singleton pregnancies
≥18 years old
Estimated gestational age less than 24 weeks
Meet criteria for an exam indicated cerclage
Patients must also be able to provide consent, demonstrate an understanding of the purpose of the study, and agree to the study protocol.
Exclusion Criteria:
Human immunodeficiency virus (HIV) positive status
Known prolonged QT syndrome
Major fetal congenital anomalies
Temperature of 100.4 F or higher
Prior cerclage during the current pregnancy
Contraindication to indomethacin
Allergy to both penicillin and clindamycin
Received indomethacin or any antibiotics within 7 days before their presentation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rupsa Boelig, MD
Phone
2159555000
Email
Rupsa.boelig@jefferson.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jenani S Jayakumaran, MD
Organizational Affiliation
Thomas Jefferson University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rupsa Boelig, MD
Organizational Affiliation
Thomas Jefferson University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emily Miller, MD
Facility Name
Rutgers Robert Wood Johnson
City
New Brunswick
State/Province
New Jersey
ZIP/Postal Code
08901
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Justin Brandt, MD
12. IPD Sharing Statement
Learn more about this trial
Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial
We'll reach out to this number within 24 hrs